17-iodoheptadecanoic-acid and Diabetes-Mellitus--Type-1

Increased triglyceride accumulation has been observed in the diabetic heart, but it is not known whether the abnormalities in myocardial fatty acid metabolism differ between insulin-dependent (IDDM) and non-insulin-dependent (NIDDM) diabetic patients or whether they are present even prior to overt diabetes. Therefore, we studied myocardial fatty acid kinetics with single-photon emission tomography using 123I-heptadecanoic acid (HDA) in four groups of men: impaired glucose tolerance (IGT) (n = 13, age 53 +/- 2 years, mean +/- SEM), IDDM (n = 8, age 43 +/- 3 years), NIDDM (n = 10, age 51 +/- 2 years) and control subjects (n = 8, age 45 +/- 4 years). Echocardiography and myocardial perfusion scintigraphy (IGT and NIDDM groups) were performed to study cardiac function and flow. In the IGT subjects, myocardial HDA beta-oxidation index was reduced by 53% (4.6 +/- 0.4 vs 9.7 +/- 1.0 mumol .min-1.100 g-1, p < 0.01) and HDA uptake by 34% (3.7 +/- 0.2 vs 5.6 +/- 0.3% of injected dose 100g, p < 0.01) compared with the control subjects. The fractional HDA amount used for beta-oxidation was lower in the IGT compared with the control subjects (43 +/- 4 vs 61 +/- 4%, p < 0.05). NIDDM patients also tended to have a lowered HDA beta-oxidation index, whereas IDDM patients had similar myocardial HDA kinetics compared to the control subjects. Myocardial perfusion imaging during the dipyridamole-handgrip stress was normal both in the IGT and NIDDM groups, indicating that abnormal myocardial perfusion could not explain abnormal fatty acid kinetics. In conclusion, even before clinical diabetes, IGT subjects show abnormalities in myocardial fatty acid uptake and kinetics. These abnormalities may be related to disturbed plasma and cellular lipid metabolism.

Topics: Adult; Analysis of Variance; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Echocardiography; Fatty Acids; Fatty Acids, Nonesterified; Glucagon; Glucose Intolerance; Heart; Humans; Iodine Radioisotopes; Male; Middle Aged; Models, Cardiovascular; Myocardium; Reference Values; Tissue Distribution; Tomography, Emission-Computed; Ventricular Function, Left

A high-yield method for labelling 17-I-heptadecanoic acid with 123I is described, and a clinical evaluation of the radiopharmaceutical is given. The labelling procedure is based on the use of a conventional ultrasonic bath. It was found that the addition of thiosulphate to the reaction medium avoids the formation of labelled side products and increases the yield considerably. The carrier-free 17-123I-heptadecanoic acid (2 mCi) in 6% human serum albumin was injected IV for heart and liver studies on selected patients with cirrhosis (alcoholic, post-necrotic) and diabetes.

Topics: Diabetes Mellitus, Type 1; Fatty Acids; Heart; Humans; Kinetics; Liver; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Myocardium; Radionuclide Imaging; Temperature; Time Factors